-
Axovant Fails To Pull The Sword From The Stone; Alzheimer's Drug Fails
Tuesday, September 26, 2017 - 12:20pm | 431Axovant Sciences Ltd (NASDAQ: AXON) suffered a setback in its phase 3 trial called MINDSET in which its exploratory drug called intepirdine failed to improve the quality of life in people suffering from Alzheimer's. The drug isn't intended to be a cure for the disease but the company expected the...